Isolation, identification, and slow-growth phenotype characterization of a clinically derived Escherichia coli from urinary tract infection
A slow-growth Escherichia coli isolate, designated E. coli 105X, was recovered from a patient with urinary-tract infection. Initial biochemical profiling misidentified it as Shigella boydii; however, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and average nucleotide identity analysis (98.67% relative to uropathogenic E. coli CFT073) unequivocally reclassified the strain as E. coli. Antimicrobial susceptibility testing revealed broad-spectrum resistance to β-lactams, aminoglycosides and fluoroquinolones, which was mediated by 53 acquired resistance determinants, including the extended-spectrum β-lactamase genes blaCTX-M-55 and blaTEM-1, together with an expanded repertoire of efflux pump systems. Whole-genome sequencing (WGS) disclosed 45399 single-nucleotide polymorphisms and 1736 insertions/deletions relative to E. coli CFT073. Functional enrichment analyses demonstrated that non-synonymous mutations in 11 flagellar biosynthesis genes (e.g., flgA, fliK), the peptidoglycan synthase-encoding mrcB, and 29 growth-associated loci collectively perturb energy allocation and compromise biofilm formation, resulting in a markedly prolonged doubling time. Concurrently, E. coli 105X lacks canonical virulence factors such as the siderophore enterobactin and P fimbriae, but has acquired temperature-sensitive hemagglutinin and type IV pili. Taken together, E. coli 105X exemplifies a distinctive adaptive strategy in which metabolic bottlenecks synergize with structural mutations to establish a "slow-growth, high-resistance, re-engineered virulence" phenotype. These findings underscore the critical necessity of molecular diagnostic tools for accurate identification of morphologically atypical clinical E. coli isolates, and provide a theoretical rationale for developing targeted combination therapies that interfere with core bacterial energy-metabolism pathways.
Authors
- Jiangling Wu (ORCID: https://orcid.org/0000-0001-5249-1110)
- Xiongyu Jiang
- Siqiang Niu (ORCID: https://orcid.org/0000-0002-8911-7138)
- Chunhong Zou
- Ranran Tang (ORCID: https://orcid.org/0000-0001-7200-3639)
- Yumei Zhao
- Xiangyu Deng
- Qiongyuan Zhang
- Yao Ou
- Shanshan Dong
- Shuqi Zhang
- Wenqiang Yu
- Dinghua Liu (ORCID: https://orcid.org/0009-0007-4743-3531)
Institutions
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2026-10-29
- DOI
- https://doi.org/10.1371/journal.pone.0358948
- Primary Topic
- Escherichia coli research studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chongqing Municipal Health Commission
- China Postdoctoral Science Foundation
- Chongqing Science and Technology Commission
- Chongqing Medical University
- Chongqing Municipal Education Commission